Xellia Pharmaceuticals has completed the expansion of its new $13 million centralized laboratory services building at its Budapest manufacturing site. The expansion strengthens Xellia’s global anti-infective product capabilities with additional product stability and release testing expertise and capabilities. The new 3,000 square-meter, multi-story building accommodates state-of-the-art microbiology and chemical analytical laboratories, a product stability center and administrative offices. I...